NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Mike, here again, just like where you mistook the word “update” for “interim steps,” in this case you are failing to distinguish between a potential evidence submission to the CDF, which, if so, wouldn’t have included the economic modeling LP stated would be required later for a STA NICE reimbursement decision.

You don’t understand the last post I just referenced to Ex regarding why LP might be one step ahead. It’s like it goes in one ear and out the other with you.

My guess is you didn’t even understand this subsection.

Companies may also informally signal to NICE early in the process that a
treatment is a potential CDF candidate (for example, during scoping).